MICHAEL R MIGDEN to Drug Administration Schedule
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Drug Administration Schedule.
Connection Strength
0.049
-
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1).
Score: 0.029
-
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
Score: 0.021